



# Abuse Liability Assessment of JL Electronic Nicotine Delivery System (ENDS) in Two Nicotine Concentrations Compared to Usual Brand Cigarette, Nicotine Gum and a Comparator ENDS

Nicholas I. Goldenson, PhD,<sup>1</sup> August R. Buchhalter, PhD,<sup>2</sup> Mark L. Rubinstein, MD,<sup>1</sup> Erik M. Augustson, PhD, MPH,<sup>1</sup> Jack E. Henningfield, PhD<sup>2</sup>

<sup>1</sup>JUUL Labs, Inc., <sup>2</sup>PinneyAssociates

Late Breaking Oral Presentation at the 82<sup>nd</sup> Annual Scientific Meeting of the College on Problems of Drug Dependence

June 22, 2020



#### **Disclosures**

NIG, EMA and MLR are full-time employees of JUUL Labs, Inc. (JLI)

ARB and JEH are full-time employees of PinneyAssociates and advise JLI on abuse liability related to JLI ENDS products.

JLI Science
This research was funded by JUUL Labs, Inc.



## Participants and Experimental Design



- Adult smokers (N=146; mean age=41.2 years; 46% female; JL ENDSnaïve)
- Randomized, parallel-cohort, crossover, open-label design
- 4 study arms (cohorts) Virginia Tobacco, Menthol, Mint, Mango
- 35-38 subjects per cohort
- Within each cohort subjects were randomized to a 5-product withinsubjects cross-over sequence
  - 1. JL END 5.0%
  - 2. JL ENDS 3.0%
  - 3. Usual brand (UB) cigarette
  - 4. 4 mg Mint Nicotine Gum (Nicorette® White Ice Mint)
  - 5. Comparator ENDS (VUSE Alto 5.0%)
- Subjects puffed the ENDS and cigarettes ad lib for 5 minutes
- Gum was chewed ad lib by "chew and park" method for 30 minutes.





## PK Parameters and Subjective Measures Presented Today:

### PK parameters

- Plasma nicotine concentration time course
- Peak nicotine levels (C<sub>max-BL</sub>)
- Rate of plasma nicotine rise  $(C_{max-BL}/T_{max})$

## Subjective measures – 100 mm visual analog scales


- Product Liking
- Urge to Smoke






Baseline-Adjusted Plasma Nicotine Concentration Profiles of Test Products 120-Minutes Post-Ad Libitum Product Use, All Cohorts

Combined (N=141-143)





## PK Parameters of Test Products, All Cohorts Combined




Note. Test products that do not share the same letter significantly differ.





# Product Liking Ratings of Test Products, All Cohorts Combined (N= 141-143) Mean (±*SE*)




Note. Test products that do not share the same letter significantly differ.



## Time Course of Mean Urge to Smoke Ratings, All Cohorts Combined





Note: N=141-143. \*Significantly different from other test products (p<0.05).



## **Conclusions**

- Use of the JL ENDS among a sample of adult smokers resulted in nicotine delivery and product appeal that were less than that of combustible cigarettes but were generally greater than nicotine gum
- The pharmacokinetic and pharmacodynamic profiles suggest that the abuse liability of both the 5.0% and 3.0% JL ENDS is:
  - 1. Lower than the UB cigarette
  - 2. Somewhat lower than the comparator ENDS (VUSE Alto)
  - 3. Higher than nicotine gum
- The abuse liability of the JL ENDS 5.0% is somewhat higher than 3.0%
- Findings are generally consistent with other JL ENDS abuse liability studies
  - E.g., Dr. Buchhalter et al. poster at this CPDD meeting
  - Dr. Goldenson et al. poster at SRNT, March 2020